18. Diener K.R., Moldenhauer L.M., Lyons A.B., Brown M.P., Hayball J.D. Human Flt-3-ligand- mobilized dendritic cells require additional activation to drive effective immune responses. Exp. Hematol., 2008, vol. 36, no. 1, pp. 51-60.
19. Chulpanova D.S., Solovyeva V.V., Kitaeva K.V., Dunham S.P., Khaiboullina S.F., Rizvanov A.A. Recombinant viruses for cancer therapy. Biomedicines, 2018, vol. 6, no. 4, art. 94, pp. 1-14.
20. Rossowska J., Anger N., Szczygiel A., Mierzejewska J., Pajtasz-Piasecka E. Intratumoral lentivector- mediated TGF-B1 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells. Front. Immunol., 2017, vol. 8, art. 713, pp. 1-15.
21. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.-P., Johnston D.A., Fay J., Banchereau J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother., 2006, vol. 29, no. 5, pp. 545-557.
22. Salcedo M., Bercovici N., Taylor R., Vereecken P., Massicard S., Duriau D., Vernel-Pauillac F., Boyer A., Baron-Bodo V., Mallard E., Bartholeyns J., Goxe B., Latour N., Leroy S., Prigent D., Martiat P., Sales F., Laporte M., Bruyns C., Romet-Lemonne J.-L., Abastado J.-P., Lehmann F., Velu T. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother., 2006, vol. 55, no. 7, pp. 819-829.
23. Squadrito M.L., Cianciaruso C., Hansen S.K., De Palma M. EVIR: Chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods, 2018, vol. 15, no. 3, pp. 183-186.
24. Chulpanova D.S., Kitaeva K.V., James V., Rizvanov A.A., Solovyeva V.V. Therapeutic prospects of extracellular vesicles in cancer treatment. Front. Immunol., 2018, vol. 9, art. 1534, pp. 1-10.
25. Block M.S., Dietz A.B., Gustafson M.P., Kalli K.R., Erskine C.L., Youssef B., Vijay G.V., Allred J.B., Pavelko K.D., Strausbauch M.A., Lin Y., Grudem M.E., Jatoi A., Klampe C.M., Wahner-Hendrickson A.E., Weroha S.J., Glaser G.E., Kumar A., Langstraat C.L., Solseth M.L., Deeds M.C., Knutson K.L., Cannon M.J. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat. Commun., 2020, vol. 11, no. 1, art. 5173, pp. 1-12.
26. Nagai K., Adachi T., Harada H., Eguchi S., Sugiyama H., Miyazaki Y. Dendritic cell-based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: A phase I/IIa clinical trial. Anticancer Res., 2020, vol. 40, no. 10, pp. 5765-5776.
27. Matsui H.M., Hazama S., Nakajima M., Xu M., Matsukuma S., Tokumitsu Y., Shindo Y., Tomo- chika S., Yoshida S., Iida M., Suzuki N., Takeda S., Yoshino S., Ueno T., Oka M., Nagano H. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: A phase I/II prospective randomized controlled clinical trial. Cancer Immunol. Immunother., 2021, vol. 70, no. 4, pp. 945-957.
28. Lukashina M.I., Smirnova A., Aliev V.A., Samoilenko I.V., Semenov N.N., Veiko V.P., Mikhailova I.N., Barsukov Yu.A., Baryshnikov A.Yu. Dendritic cell vaccines in colorectal cancer therapy. Vestn. RONTs im. N.N. Blokhina Ross. Akad. Med. Nauk, 2008, vol. 19, no. 3, pp. 35-42. (In Russian)
29. Fadeev F.A., Zamyatin A.V., Sedneva-Lugovets D.V., Mikerov I.A., Gubaeva O.V. Generation of dendritic cells for cancer therapy. Vestn. Ural. Med. Akad. Nauki, 2020, vol. 17, no. 4, pp. 347-353.
30. Bulgarelli J., Tazzari M., Granato A.M., Ridolfi L., Maiocchi S., de Rosa F., Petrini M., Pancisi E., Gentili G., Vergani B., Piccinini F., Carbonaro A., Leone B.E., Foschi G., Ancarani V., Framarini M., Guidoboni M. Dendritic cell vaccination in metastatic melanoma turns “non-T cell inflamed” into “T-cell inflamed” tumors. Front. Immunol., 2019, vol. 10, art. 2353, pp. 1-13.
31. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., Chen S., Klein A.P., Pardoll D.M., Topalian S.L., Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 2012, vol. 4, no. 127, art. 127ra37, pp. 1-22.
32. Wilgenhof S., Corthals J., Heirman C., van Baren N., Lucas S., Kvistborg P., Thielemans K., Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J. Clin. Oncol., 2016, vol. 34, no. 12, pp. 1330-1338.
33. Jansen Y., Kruse V., Corthals J., Schats K., van Dam P.-J., Seremet T., Heirman C., Brochez L., Kockx M., Thielemans K., Neyns B. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol. Immunother., 2020, vol. 69, no. 12, pp. 2589-2598.
34. Boudewijns S., Bloemendal M., de Haas N., Westdorp H., Bol K.F., Schreibelt G., Aarntzen E.H.J.G., Lesterhuis W.J., Gorris M.A.J., Croockewit A., van der Woude L.L., van Rossum M.M., Welzen M., de Goede A., Hato S.V., van der Graaf W.T.A., Punt C.J.A., Koornstra R.H.T., Gerritsen W.R., Figdor C.G., de Vries I.J.M. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: A prospective, randomized phase 2 trial. Cancer Immunol. Immunother., 2020, vol. 69, no. 3, pp. 477-488.
35. Petenko N.N., Mikhailova I.N., Chkadua G.Z., Demidov L.V., Baryshnikov A.Yu. Dendritic cell vaccine therapy after radical surgery for cutaneous melanoma. Sarkomy Kostei, Myagkikh Tkanei Opukholi Kozhi, 2022, no. 1, pp. 43-49. (In Russian)
36. Sturm D., Bender S., Jones D.T., Lichter P., Grill J., Becher O., Hawkins C., Majewski J., Jones C., Costello J.F., Iavarone A., Aldape K., Brennan C.W., Jabado N., Pfister S.M. Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat. Rev. Cancer, 2014, vol. 14, no. 2, pp. 92-107.
37. Polyzoidis S., Ashkan K. DCVax®-L-developed by Northwest Biotherapeutics. Hum. Vaccines Immunother., 2014, vol. 10, no. 11, pp. 3139-3145
38. Liau L.M., Ashkan K., Tran D.D., Campian J.L., Trusheim J.E., Cobbs C.S., Heth J.A., Salacz M., Taylor S., D'Andre S.D., Iwamoto F.M., Dropcho E.J., Moshel Y.A., Walter K.A., Pillainaya- gam C.P., Aiken R., Chaudhary R., Goldlust S.A., Bota D.A., Duic P., Grewal J., Elinzano H., Toms S.A., Lillehei K.O., Mikkelsen T., Walbert T., Abram S.R., Brenner A.J., Brem S., Ewend M.G., Khagi S., Portnow J., Kim L.J., Loudon W.G., Thompson R.C., Avigan D.E., Fink K.L., Geoffroy F.J., Lindhorst S., Lutzky J., Sloan A.E., Schackert G., Krex D., Meisel H.-J., Wu J., Davis R.P., Duma C., Etame A.B., Mathieu D., Kesari S., Piccioni D., Westphal M., Baskin D.S., New P.Z., Lacroix M., May S.-A., Pluard T.J., Tse V., Green R.M., Villano J.L., Pearlman M., Petrecca K., Schulder M., Taylor L.P., Maida A.E., Prins R.M., Cloughesy T.F., Mulholland P., Bosch M.L. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med., 2018, vol. 16, no. 1, art. 142, pp. 1-9.
39. Mitsuya K., Akiyama Y., Iizuka A., Miyata H., Deguchi S., Hayashi N., Maeda C., Kondou R., Kanematsu A., Watanabe K., Ashizawa T., Abe Y., Ito I., Oishi T., Sugino T., Nakasu Y., Yama- guchi K. Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: A phase II clinical trial. Anticancer Res., 2020, vol. 40, no. 11, pp. 6473-6484.
40. Wang Q.-T., Nie Y., Sun S.-N., Lin T., Han R.-J., Jiang J., Li Z., Li J.-Q., Xiao Y.-P., Fan Y.-Y., Yuan X.-H., Zhang H., Zhao B.-B., Zeng M., Li S.-Y., Liao H.-X., Zhang J., He Y.-W. Tumor- associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol. Immunother., 2020, vol. 69, no. 7, pp. 1375-1387.
41. Lutsuk R.A., Olyushin V.E., Tastanbekov M.M., Rostovtsev D.M., Papayan G.V., Filatov M.V., Sebelev K.I., Zabrodskaya Yu.M., Maslova L.N. Photodynamic therapy and specific immunotherapy based on autologous dendritic cells in treating patients with recurrent malignant gliomas. Ross. Neirokhir. Zh. im. Professora A.L. Polenova, 2018, vol. 10, no. 2, pp. 71-78. (In Russian)
42. Hlavackova E., Pilatova K., Cerna D., Selingerova I., Mudry P., Mazanek P., Fedorova L., Mer- hautova J., Jureckova L., Semerad L., Pacasova R., Flajsarova L., Souckova L., Demlova R., Sterba J., Valik D., Zdrazilova-Dubska L. Dendritic cell-based immunotherapy in advanced sarcoma and neuroblastoma pediatric patients: Anti-cancer treatment preceding monocyte harvest impairs the immunostimulatory and antigen-presenting behavior of DCs and manufacturing process outcome. Front. Oncol., 2019, vol. 9, art. 1034, pp. 1-15.
43. Raj S., Bui M.M., Springett G., Conley A., Lavilla-Alonso S., Zhao X., Chen D., Haysek R., Gonzalez R., Letson G.D., Finkelstein S.E., Chiappori A.A., Gabrilovitch D.I., Antonia S.J. Long-term clinical responses of neoadjuvant dendritic cell infusions and radiation in soft tissue sarcoma. Sarcoma, 2015, vol. 2015, art. 614736, pp. 1-8.
44. Fedorova L., Mudry P., Pilatova K., Selingerova I., Merhautova J., Rehak Z., Valik D., Hlavackova E., Cerna D., Faberova L., Mazanek P., Pavelka Z., Demlova R., Sterba J., Zdrazilova-Dubska L. Assessment of immune response following dendritic cell-based immunotherapy in pediatric patients with relapsing sarcoma. Front. Oncol., 2019, vol. 9, art. 1169, pp. 1-12.
45. Cox M.C., Castiello L., Mattei M., Santodonato L., D'Agostino G., Muraro E., Martorelli D., La- penta C., Di Napoli A., Di Landro F., Cangemi M., Pavan A., Castaldo P., Hohaus S., Donati S., Montefiore E., Berdini C., Carlei D., Monque D.M., Ruco L., Prosperi D., Tafuri A., Spadaro F., Sestili P., Spada M., Dolcetti R., Santini S.M., Rozera C., Arico E., Capone I., Belardelli F. Clinical and antitumor immune responses in relapsed/refractory follicular lymphoma patients after intranodal injections of IFNa-dendritic cells and rituximab: A phase I clinical trial. Clin. Cancer Res., 2019, vol. 25, no. 17, pp. 5231-5241.
46. Lin Y., Atwell T., Weisbrod A., Maas M., Armstrong A., Deeds M., Bulur P., Gustafson M., Zhang Z., Cordes S., Porrata L., Markovic S., Johnston P., Micallef I., Inwards D., Colgan J., Ansell S., Gastineau D., Dietz A., Witzig T. Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: Clinical trial in progress. Cytotherapy, 2015, vol. 17, no. 6, suppl., p. S17.